ERBB2 and breast cancer: This counterintuitive result was similar to that observed by Jordan et al60 using circulating tumour cells from a BC patient sorted into HER2− and HER2 + subpopulations, which were found to be equally sensitive to Lapatinib (another HER2 inhibitor), but no mechanism of action was put forward.